Stock data
Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc. (ABOS) reported net income of -US$121.33M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$123.83M | -US$121.33M | — |
| 2024 | — | — | -US$114.02M | -US$102.33M | — |
| 2023 | — | — | -US$61.14M | -US$52.37M | — |
| 2022 | — | — | -US$45.24M | -US$42.86M | — |
| 2021 | — | — | -US$19.58M | -US$100.61M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$32.72M | — |
| 2026-03-31 | — | -US$20.74M | — |
| 2025-12-31 | — | -US$25.14M | — |
| 2025-09-30 | — | -US$26.45M | — |
| 2025-06-30 | — | -US$40.95M | — |
| 2025-03-31 | — | -US$28.80M | — |
| 2024-12-31 | — | -US$37.15M | — |
| 2024-09-30 | — | -US$29.77M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.